Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (NASDAQ:UTHR), filed a Form 4 on August 31, 2026, disclosing the exercise of 9,500 stock options and the sale of 9,500 shares of common stock on August 28, 2026, all conducted through a trust under a pre-arranged Rule 10b5-1 trading plan.
Key Highlights
- Option exercise: Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share, held indirectly through a family trust.
- Shares sold: A total of 9,500 shares were sold across eleven separate tranches on August 28, 2026, at weighted average prices ranging from $514.257 to $524.4175.
- 10b5-1 plan: The transactions were made pursuant to a pre-arranged trading plan adopted by Rothblatt on November 7, 2025, according to the filing.
- Plan scope: The plan covers up to 1,734,410 stock options, all expiring on March 15, 2027, and runs until the earlier of full exercise or December 31, 2026.
- Remaining beneficial ownership: Following the transactions, Rothblatt's total reported beneficial ownership across all forms of direct and indirect holdings includes 40,513 shares held directly and 324,443 shares held indirectly through various trusts, among other interests.
- Remaining options: 37,410 stock options remain beneficially owned indirectly through a family trust after the reported exercise.
Rothblatt Option Exercise and Share Sales: Transaction Details
According to the filing, Rothblatt exercised 9,500 stock options on August 28, 2026, with an exercise price of $135.42 per share and an expiration date of March 15, 2027. The options were held in a family trust in which the reporting person shares investment power and the reporting person and immediate family members are beneficiaries. The filing notes the exercise price of the derivative security as $0.00 at the time of exercise.
The 9,500 resulting shares were then sold in eleven separate tranches on the same date at weighted average prices from $514.257 to $524.4175 per share. The filing states that each sale tranche was executed across multiple individual trades, and Rothblatt "undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected." All sales were conducted indirectly through a family trust. All transactions are attributed by the filing to a 10b5-1 plan adopted on November 7, 2025.
The filing also discloses separate holdings not involved in the reported transactions: 166 shares held indirectly by a spouse, 249,108 shares in family trusts where the reporting person's spouse is sole trustee or co-trustee, 45,596 shares in trusts where the spouse shares investment power, and 8,902 shares in trusts where Rothblatt serves as sole trustee or co-trustee and settlor. The filing was signed by John S. Hess, Jr. under Power of Attorney on August 31, 2026.
What Was Disclosed
The filing reports the exercise of 9,500 stock options and the sale of 9,500 common shares of United Therapeutics Corp by CEO Martine A. Rothblatt on August 28, 2026, all conducted indirectly through a family trust under a pre-arranged 10b5-1 trading plan.




Please wait processing your request...